IoT in Healthcare Market to Reach US$594.5 Bn by 2035 at 23.85% CAGR | Vantage Market Research 
Agape ATP Corporation Receives Nasdaq Notice on Minimum Bid Price Requirement
KUALA LUMPUR, MY / ACCESS Newswire / January 29, 2026 / Agape ATP Corporation (NASDAQ:ATPC) ("ATPC" or "the Company") announced...
VSee and DocBox Announce Strategic Partnership to Launch the First Augmented Intelligence Platform for Virtual ICU
Creating a scalable, AI‑native Virtual ICU platform that drives new recurring revenue and enterprise value. SAN JOSE, CALIFORNIA / ACCESS...
Aspire Biopharma Secures Agreement with Microsize for Development of Novel Sublingual Aspirin
Microsize brings over thirty years of expertise in specialized particle size engineering for the pharmaceutical industry, from pre-clinical development to...
Yunu Extends from Site Imaging Standard to Central Review Workflow Leader
New Imaging Automation Delivers a Modern Framework for Central Review & Site Collaboration CARY, NORTH CAROLINA / ACCESS Newswire /...
Breakthru Medicine emerges from stealth with $60M Series A for cancer drug development
PHOENIX, Ariz., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Breakthru Medicine emerges from stealth with the close of a $60M Series...
Profusa Presents Positive US-Study Clinical Results at Leipzig Interventional Course (LINC) 2026
Study conducted at US sites evaluates LumeeTM in peripheral artery disease (PAD) patients BERKELEY, Calif, Jan. 29, 2026 (GLOBE NEWSWIRE)...
Immutep Quarterly Activities Report Q2 FY26
Media Release Entered into strategic collaboration with Dr. Reddy’s for commercialisation of eftilagimod alfa (efti) in all countries outside North...
Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor
REDWOOD CITY, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for...
InnovAge Expands Board with Appointment of Two Directors
DENVER, Jan. 29, 2026 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in...
Belite Bio Announces Participation at the 41st Asia-Pacific Academy of Ophthalmology Congress (APAO)
SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage...
Beghou’s Biopharma Commercialization Research Report Reveals Top Challenges, Opportunities, and Investment for Life Sciences Industry in 2026
New research shows teams are struggling to execute coordinated actions across data, access, and omnichannel, leading to persistent gaps in...
Apyx Medical Corporation to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
CLEARWATER, Fla., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in...
Soleno Therapeutics to Participate in Upcoming Conferences
REDWOOD CITY, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel...
InflaRx Announces Participation in February Investor Conferences
JENA, Germany, Jan. 29, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting...
Glass House Brands Announces Appointment of Alison Payne, Heineken USA Chief Marketing Officer, to its Board of Directors
Ms. Payne brings decades of international marketing experience from Heineken, PepsiCo, Kellog and Diageo, where she specializes in branding regulated...
Vivani Subsidiary Cortigent Presents Promising 6-Year Early Feasibility Study Results for the Orion System at NANS 2026
Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology Cortigent is the only company to...
Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference
SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on...
Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel...
Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita® After GLP-1 Discontinuation
Revita-treated patients experienced sustained weight maintenance, improved cardiometabolic profile, and reduced food cravings at 6 months compared with sham, with...
Terrapin Beer Co. Turns Up the Volume with a New Brand Identity Rooted in Music, Art and Craft Beer Culture
A modern visual evolution designed to amplify artistic storytelling across the brand portfolioATHENS, Ga., Jan. 29, 2026 (GLOBE NEWSWIRE) --...